Freenome, Inc.
Support and Resistance Levels
Past performance
News About FRNM
All events for FRNM
All deals for FRNM
Financial Ratios
Financial Statements
FRNM vs Sector & Peers
About Freenome, Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA). Website freenome.com
Headquarters Brisbane, CA, US